◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › IRWD

Ironwood Pharmaceuticals Inc (IRWD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-23

Ironwood Pharmaceuticals Inc (IRWD) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Boston, United States with about 100 employees. Its market capitalization is roughly $578 million. In the fiscal year ended 2025-12-31, IRWD reported $296M in revenue and $24M in net income.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

Interactive charts & full statements → Open the IRWD valuation workbench →

IRWD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$389M	$296M	$351M	$443M	$411M	$414M	$390M	$428M	$347M	$298M	$274M	$150M	$76M	$23M	$150M	$66M	$44M	$36M	$22M	$10M	$3M
Gross Profit	$388M	$296M	$344M	$437M	$409M	$343M	$386M	$293M	$314M	$279M	$272M	$150M	$51M	$16M	$149M	$66M	$44M	$36M	$22M	$10M	—
Gross Margin %	99.8%	100.0%	97.9%	98.6%	99.7%	83.0%	99.2%	68.4%	90.5%	93.5%	99.3%	100.0%	66.5%	68.5%	99.4%	100.0%	100.0%	100.0%	100.0%	100.0%	—
Operating Income (EBIT)	$236M	$119M	$93M	($945M)	$250M	$232M	$143M	$120M	($239M)	($77M)	($52M)	($102M)	($169M)	($252M)	($73M)	($66M)	($61M)	($73M)	($56M)	($58M)	($40M)
Operating Margin %	60.6%	40.1%	26.5%	-213.5%	61.0%	56.1%	36.7%	28.0%	-68.9%	-25.9%	-18.9%	-68.3%	-221.6%	-1101.4%	-48.4%	-100.4%	-138.5%	-201.6%	-251.7%	-550.6%	-1261.0%
Net Income	$130M	$24M	$1M	($1.0B)	$175M	$528M	$106M	$22M	($282M)	($117M)	($82M)	($143M)	($190M)	($273M)	($73M)	($65M)	($53M)	($71M)	($54M)	($53M)	($37M)
Net Margin %	33.4%	8.1%	0.2%	-226.4%	42.6%	127.7%	27.3%	5.0%	-81.5%	-39.2%	-29.8%	-95.4%	-248.1%	-1192.3%	-48.3%	-98.5%	-120.8%	-197.2%	-242.5%	-504.1%	-1184.1%
EBITDA	$241M	$105M	$98M	$197M	$261M	$234M	$142M	$129M	($144M)	($33M)	($31M)	($100M)	($157M)	($240M)	($61M)	($55M)	($53M)	($67M)	($52M)	($51M)	($36M)
Earnings Per Share (EPS)	$0.77	$0.14	$0.01	$-6.45	$0.94	$3.21	$0.66	$0.14	$-1.85	$-0.78	$-0.56	$-1.00	$-1.39	$-2.35	$-0.68	$-0.65	$-0.59	$-1.02	$-0.77	$-0.70	$-0.39
Shares Outstanding (M)	165M	178M	160M	155M	186M	164M	161M	156M	153M	149M	146M	142M	137M	116M	106M	100M	90M	70M	70M	76M	95M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRWD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$113M	$107M	$48M	$122M	$85M	$41M	$91M	$92M
Gross Profit	$113M	$106M	$48M	$122M	$85M	$14M	$91M	$62M
Gross Margin %	100.0%	99.6%	100.0%	99.6%	99.5%	33.3%	100.0%	67.4%
Operating Income (EBIT)	$79M	$73M	$7M	$78M	$45M	($29M)	$31M	$26M
Operating Margin %	70.2%	68.1%	13.7%	63.6%	52.9%	-70.8%	34.8%	28.0%
Net Income	$51M	$41M	($2M)	$40M	$24M	($37M)	$2M	$4M
Net Margin %	45.4%	38.3%	-4.8%	32.8%	27.7%	-90.9%	2.5%	4.0%
EBITDA	$81M	$75M	$9M	$77M	$47M	($10M)	$33M	$27M
Earnings Per Share (EPS)	$0.31	$0.24	$-0.01	$0.23	$0.15	$-0.23	$0.01	$0.02
Shares Outstanding (M)	165M	167M	178M	178M	162M	161M	160M	160M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRWD Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$186M	$127M	$104M	$183M	$274M	$262M	$169M	$11M	($71M)	($100M)	($25M)	($107M)	($156M)	($273M)	($70M)	($75M)	($68M)	($4M)	($28M)	($7M)	($34M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$2M	$7M	$9M	$4M	$104M	$4M	$4M	$10M	$14M	$10M	$17M	$4M	$23M	$3M	$3M
Free Cash Flow (FCF)	$186M	$127M	$103M	$183M	$274M	$262M	$167M	$4M	($80M)	($104M)	($130M)	($111M)	($159M)	($283M)	($84M)	($85M)	($85M)	($8M)	($51M)	($9M)	($36M)
FCF Margin %	47.7%	42.9%	29.4%	41.4%	66.6%	63.2%	42.9%	0.8%	-22.9%	-34.8%	-47.3%	-74.2%	-208.2%	-1236.6%	-55.6%	-128.9%	-194.1%	-22.3%	-230.1%	-89.9%	-1157.8%
Dividends Paid	—	—	—	—	$111M	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRWD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$58M	$5M	$75M	$48M	($15M)	$20M	$15M	$10M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$58M	$5M	$75M	$48M	($15M)	$20M	$15M	$10M
FCF Margin %	51.5%	4.8%	156.3%	39.0%	-17.7%	48.4%	16.8%	10.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IRWD Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Assets	$285M	$397M	$351M	$471M	$1.1B	$1.1B	$559M	$403M	$332M	$606M	$710M	$619M	$334M	$279M	$230M	$209M	$301M	$162M	$141M	$136M
Cash & Cash Equivalents	$79M	$215M	$89M	$92M	$656M	$620M	$364M	$177M	$173M	$126M	$54M	$261M	$74M	$75M	$137M	$87M	$44M	$123M	$68M	$62M
Total Liabilities	$447M	$659M	$652M	$817M	$448M	$521M	$497M	$496M	$528M	$596M	$643M	$524M	$245M	$241M	$86M	$99M	$142M	$461M	$371M	$314M
Total Debt (Short + Long-Term)	$388M	$588M	$587M	$701M	$399M	$457M	$433M	$409M	$414M	$400M	$373M	$384M	$176M	$176M	$1M	$1M	$1M	$3M	$2M	$3M
Total Shareholders' Equity	($162M)	($262M)	($301M)	($346M)	$652M	$606M	$63M	($93M)	($196M)	$10M	$67M	$95M	$89M	$38M	$144M	$110M	$160M	($302M)	($236M)	($185M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IRWD viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

PCRX · Pacira BioSciences, Inc. — $1 billion
CRON · Cronos Group Inc — $1 billion
HROW · Harrow Health Inc — $1 billion
COLL · Collegium Pharmaceutical Inc — $773 million
EVO · Evotec SE ADR — $551 million
AQST · Aquestive Therapeutics Inc — $487 million
EOLS · Evolus Inc — $487 million
TKNO · Alpha Teknova Inc — $454 million

← IRVH All “I” companies IS-FF101 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.